Drugs associated with development of pityriasis rubra pilaris: A systematic review - 10/03/21
Funding sources: Dr Lytvyn was supported by the Canadian Association of Psoriasis Patients Studentship. |
|
Conflicts of interest: Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Dr Mufti, Dr Lytvyn, Mr Maliyar, and Ms Sachdeva have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 84 - N° 4
P. 1071-1081 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?